VJOncology Podcast

St. Gallen highlights: controversies in the axilla

In this podcast, Icro Meattini (University of Florence, Florence, Italy) and Orit Kaidar-Person (Sheba Medical Center, Ramat Gan, Israel) discuss updates and controversies in the axillary management of breast cancer, live at the St Gallen Breast Cancer Consensus 2023.

Radiotherapy Highlights from ASCO GU 2023 with Sophia Kamran, Himanshu Nagar, and Neha Vapiwala

In this podcast, hear from GU cancer experts Sophia Kamran (Massachusetts General Hospital and Harvard Medical School, Boston, MA), Himanshu Nagar (Weill Cornell Medicine and New York Presbyterian, New York City, NY), and Neha Vapiwala (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA) as they discuss the highlights in radiation oncology for GU cancers at the ASCO GU Cancers Symposium 2023.

In prostate cancer, key radiation oncology trials included FORMULA-509 (NCT03141671), RADICALS-HD (NCT00541047), CHHiP, and PACE-A. In bladder cancer, hot topics of discussion included the use of adaptive radiotherapy and a debate on when to use bladder-only or whole-pelvis radiotherapy. Finally, in testicular cancer, a key discussion compared the use of radiotherapy vs surgery vs chemotherapy for the treatment of stage 2a seminoma.

Chemotherapy, post-adjuvant therapy, and clinical trial ethics at St Gallen BCC 2023

The St Gallen Breast Cancer Congress took place on the 15-18 March 2023. Leading researchers and experts were brought together in Vienna, Austria, to discuss and debate the most important updates in breast cancer. In this podcast, we’ll run through research updates spanning from early treatment to post-adjuvant therapy and a taste of the ethical considerations involved in recruiting for clinical trials. We’ll be hearing from Prof. Philip Poortmans of AZ Sint-Augustinus – Oncologisch Centrum GZA, Dr Lisa Carey of UNC Lineberger Comprehensive Cancer Center, Dr Marleen Kok of the Netherlands Cancer Institute, Dr Hope S. Rugo of Helen Diller Family Comprehensive Cancer Center, Dr Sara Tolaney of Dana-Farber Cancer Institute, and Dr Orit Kaidar-Person of Sheba Medical Center, about new developments in our understanding of appropriate chemotherapy and immunotherapy options, as well as the importance of this conference in progressing clinical practice for breast cancer.

 

Key Trials from ASCO GU 2023 with Scott Tagawa, Karie Runcie, and Tanya Dorff

In this episode, join GU cancer experts Scott Tagawa (Weill Cornell Medicine and New York Presbyterian, New York City, NY), Karie Runcie (Columbia University Irving Medical Center, New York City, NY), and Tanya Dorff (City of Hope Comprehensive Cancer Center, Duarte, CA) as they discuss the most important clinical trial data for prostate, bladder, and kidney cancer at the ASCO GU Cancers Symposium 2023.

In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).

Biomarkers, patient selection, and immunotherapy at ESMO Gynae 2023

In this episode, we'll hear from Marcia Hall, Eric Pujade-Lauraine, and Mansoor Raza Mirza, who will share their expertise and insights on the latest developments in gynecological cancer research and treatment from ESMO Gynae 2023.

First, we will hear about a study exploring the use of circulating tumor cells as a potential biomarker for predicting response to therapy. Dr Hall discusses how this study has the potential to revolutionize cancer treatment and diagnosis, and what the implications of these findings are for future research.

Prof. Pujade-Lauraine updates us on the findings from the PAOLA-1 trial, which evaluated the use of maintenance olaparib plus bevacizumab in patients with ovarian cancer. He discuss the importance of patient selection in ovarian cancer, and how these updated findings can inform treatment decisions for patients.

Finally, Dr. Mirza shares his insights on the potential of combination therapies, personalized medicine, and immunotherapy in the treatment of endometrial cancer. He discusses how these new approaches are changing the way we think about treatment, and what the future holds for patients with endometrial cancer.

Hot topics in renal cell carcinoma and rare tumors

In this podcast we’ll hear from experts in GU cancer on some of the most exciting clinical trial data in kidney cancer as well as some of the latest developments in rare tumors presented at the 2023 ASCO Genitourinary Cancers congress. We will be joined by Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, Michael Atkins, MD, Lombardi Comprehensive Cancer Center, Washington DC, Talal El Zarif, MD, Dana-Farber Cancer Institute, Boston, MA, Lucia Nappi, MD, University of British Columbia, Vancouver, Canada, Robert A. Huddart, PhD, FRCR, MRCP, MBBS, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK.

We will hear about outcomes by IMDC risk in the COSMIC-313 trial assessing cabozantinib plus nivolumab and ipilimumab and treatment-free survival outcomes of the HCRN G16-260 trial of nivolumab plus ipilimumab in advanced renal cell carcinoma. We’ll also discuss a longitudinal evaluation of plasma miR371 to detect minimal residual disease and early relapse of germ cell tumors and talk on the safety and efficacy of immune checkpoint inhibitors in penile squamous cell carcinoma, as well as the comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma from the TRISST trial.

Key data and hot topics in prostate cancer at ASCO GU 2023

In this episode, we’ll be hearing from GU cancer experts about some of the biggest prostate cancer data presented at the ASCO Genitourinary Cancers Symposium 2023, including TRITON3, CheckMate650, and FORMULA-509. We’ll also be hearing perspectives on some of the hot topics in the field, such as treatment sequencing and combination therapies, unanswered questions for the use of PSMA PET in the staging of disease, and the use of active surveillance in localized prostate cancer.

 

Join Alan Bryce, MD, Mayo Clinic, Rochester, MN, Russell Kent Pachynski, MD, Washington University School of Medicine, St. Louis, MO, Paul Nguyen, MD, Dana-Farber Cancer Institute, Boston, MA, Silke Gillessen, MD, Oncological Institute of Southern Switzerland, Bellinzona, Switzerland, David Nanus, MD, Weill Cornell Medicine and New York Presbyterian Hospital, New York City, NY, and Anthony Victor D'Amico, MD, PhD, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, as they discuss the latest developments in prostate cancer.

Hot Topics in Bladder Cancer at ASCO GU 2023

In this podcast, we dive deep into some of the most exciting advances in bladder cancer research that were presented at the 2023 ASCO Genitourinary Cancers congress. We will hear from Kyle Rose, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Robert Huddart, PhD, FRCR, MRCP, MBBS, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK, Aristotelis Bamias, MD, National and Kapodistrian University of Athens, Athens, Greece, and Andrea Necchi, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy. We'll be discussing some of the most highly anticipated clinical trials that were presented at the conference, including IMvigor130 and KEYNOTE-057. We'll also explore the use of circulating cell-free DNA to detect minimal residual disease, as well as the potential of adaptive image-guided radiotherapy. Join us as we explore these hot topics in bladder cancer research and hear from the experts themselves about what these developments mean for the future of bladder cancer treatment.

 This podcast recording took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

 

Approaches to NSCLC With or Without Targetable Mutations

In this podcast, we will explore approaches to non-small cell lung cancer
(NSCLC) with and without targetable mutations. NSCLC is the most
common type of lung cancer, and while significant strides have been
made in its management, there are still areas of unmet need. Our
speakers, Luis Raez, MD, FACP, FCCP, from Memorial Healthcare System in
Pembroke Pines, FL, Melissa Johnson, MD, Sarah Cannon Research
Institute, Nashville, TN, and Jorge Nieva, MD, from the University of
California, San Francisco, CA, share the current treatment landscape for
patients with NSCLC with and without targetable mutations, highlighting
recent trial results, and challenges associated with sequencing of
therapies.

CAR-T in solid tumors: advances and challenges in targeting CLDN18.2, HER2 and STEAP 1

Whilst CAR-T cell therapies have found considerable success in targeting hematological malignancies, major hurdles remain in the solid tumor space. Novel targets such as claudin 18.2 (CLDN18.2), and innovative strategies have led to encouraging results in solid tumors. In this podcast, we will hear from Gregory P. Botta, MD, PhD, UC San Diego Medical Center, San Diego, CA, Jon Amund Kyte, MD, PhD, University of Oslo, Oslo, Norway, Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, and Andras Heczey, MD, Baylor College of Medicine, Houston, TX, as they share their expert insights in this ever-expanding field.